Excelsior Biopharma Inc. (6496.TWO)
TWD 30.0
(0.0%)
TWD 30.0
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -134.75 Million | 5.48 Million | 55.82 Million | 520.81 Million | - |
| Net Income | -81.95 Million | -25.99 Million | -10.02 Million | 45.29 Million | - |
| Depreciation & Amortization | 46.21 Million | 26.06 Million | 28.64 Million | 27.36 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 262 Thousand | 37 Thousand | - | - | - |
| Change in working capital | -97.94 Million | 16.03 Million | 32.61 Million | 459.06 Million | - |
| Other non-cash items | 1.12 Million | -878 Thousand | 3.98 Million | 1.68 Million | - |
| Investing Cash Flow | 146.61 Million | -199.24 Million | -10.67 Million | 26.93 Million | - |
| Investments in PPE | -35.65 Million | -7.78 Million | -2.87 Million | -11.61 Million | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | - | -5.82 Million | -4.75 Million | - |
| Sales/Maturities of investments | 199.74 Million | -200 Million | -176 Thousand | 36.93 Million | - |
| Other Investing Activities | -17.46 Million | 8.53 Million | -1.79 Million | 6.37 Million | - |
| Financing Cash Flow | -317.22 Million | -13.72 Million | -83.04 Million | 243.51 Million | - |
| Debt repayment | -299.3 Million | - | - | -300.63 Million | - |
| Dividends payments | - | - | -46.66 Million | -46.66 Million | -186.66 Million |
| Common Stock Repurchased | - | - | -23.73 Million | - | - |
| Common Stock Issuance | - | - | - | - | - |
| Other Financing Activities | -17.92 Million | - | - | - | - |
| Accounts receivables | -26.33 Million | - | - | - | - |
| Accounts payables | -16.92 Million | - | - | - | - |
| Inventory | -28.7 Million | 16.02 Million | 71.87 Million | 139.88 Million | - |
| Other working capital | -42.9 Million | - | - | - | - |
| Cash at beginning of period | 895.27 Million | 1.1 Billion | 1.14 Billion | 349.39 Million | - |
| Cash at end of period | 589.91 Million | 895.27 Million | 1.1 Billion | 1.14 Billion | - |
| Capital Expenditure | -35.65 Million | -7.78 Million | -2.87 Million | -11.61 Million | - |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -305.35 Million | -207.48 Million | -37.89 Million | 791.26 Million | - |
| Free Cash Flow | -170.4 Million | -2.29 Million | 52.94 Million | 509.19 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -19.72 Million | -32.8 Million | -81.95 Million | 8.54 Million | -34.8 Million | -33.8 Million |
| Depreciation & Amortization | 18.14 Million | 17.07 Million | 46.21 Million | 16.76 Million | 16.95 Million | 6.4 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 102 Thousand | 102 Thousand | 262 Thousand | 101 Thousand | 88 Thousand | 37 Thousand |
| Change in working capital | -12.5 Million | 14.83 Million | -97.94 Million | -52.5 Million | -9.25 Million | -17.12 Million |
| Other non-cash items | 542 Thousand | 1.61 Million | 1.12 Million | -507 Thousand | 1.9 Million | -1.29 Million |
| Investing Cash Flow | -10.75 Million | -187.36 Million | 146.61 Million | -27.11 Million | 182.9 Million | -5.98 Million |
| Investments in PPE | -17.15 Million | -187.18 Million | -35.65 Million | -26.76 Million | -2.53 Million | -4.21 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | 199.74 Million | -258 Thousand | 200 Million | - |
| Other Investing Activities | 6.39 Million | -180 Thousand | -17.46 Million | -94 Thousand | -14.55 Million | -1.76 Million |
| Financing Cash Flow | -12.85 Million | 96.59 Million | -317.22 Million | -306.17 Million | -3.85 Million | -3.65 Million |
| Debt repayment | -13.46 Million | -110 Million | -299.3 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 609 Thousand | - | - | - | - | - |
| Accounts receivables | -10.9 Million | - | - | - | - | - |
| Accounts payables | -7.38 Million | - | - | - | - | - |
| Inventory | -20.67 Million | -23.03 Million | -28.7 Million | -299 Thousand | -37.3 Million | 14.2 Million |
| Other working capital | 26.46 Million | - | - | - | - | - |
| Cash at beginning of period | 497.72 Million | 589.91 Million | 895.27 Million | 948.99 Million | 798.41 Million | 855.21 Million |
| Cash at end of period | 456.03 Million | 497.72 Million | 589.91 Million | 589.91 Million | 948.99 Million | 798.41 Million |
| Capital Expenditure | -17.15 Million | -187.18 Million | -35.65 Million | -26.76 Million | -2.53 Million | -4.21 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | -41.68 Million | -92.19 Million | -305.35 Million | -359.07 Million | 150.57 Million | -56.79 Million |
| Free Cash Flow | -35.22 Million | -188.6 Million | -170.4 Million | -52.54 Million | -31.01 Million | -51.37 Million |
WJG
WRN
APAJF
ABB
6492
6719